Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Corporate Update (December 2022)
34 slides from Cellectis's corporate update, December 2022
Slide 1: Cellectis Clinical Update
Commitment to a Cure Cellec%s Clinical Update December 2022 NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA 1
Slide 2: Legal Notices
Legal Notices This presentation (together with the corresponding webcast, this “Presentation”) contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. This Presentation shall not constitute an offer to se
Slide 3: Legal Notices
Legal No-ces References in this Presentation to Cellectis’ product candidates as “off-the-shelf” refers to the fact that our CAR T-cells are allogeneic, meaning they are derived from healthy donors rather than the patients themselves, which we believe allows for the development of cost-effective pro
Slide 4: Cellectis at a Glance
Cellectis at a Glance 4 Ongoing Clinical Trials Global GMP FaciliAes Near-Term Clinical Catalyst $103M as of Sept 30, 2022 40+ pa@ents dosed in • Operational since 2021 • End-to-end manufacturing • UCART clinical data updates Expected Cash Runway Cellec@s-sponsored trials autonomy into 2024* Diversi
Slide 5: UCARTs are Off-The-Shelf
UCARTs are “Off-The-Shelf” Scalable Manufacturing Robustness Market Access Reduced cost The goal is to provide Immediately available to Scalable manufacturing: potency and consistency to eligible pa=ents 1 batch = 100s of doses each pa=ent 5
Slide 6: Cellectis' UCART Candidate Platform
Cellectis’ UCART Candidate Platform CAR20 CAR22 Targe\ng CD20 & CD22 For B-cell Malignancies TALEN® Powered TRAC KO Targe@ng CD22 Reduces risk of GvHD CAR22 For B-cell ALL CD52 KO Resistance to alemtuzumab Targeting CD123 CAR123 For AML or CS1 KO Self-lymphodeple8ng Targeting CS1/SLAMF7 CARCS1 For M
Slide 7: AMELI-01: UCART123
AMELI-01: UCART123 7
Slide 8: AMELI-01: Preliminary Results from a Phase I Trial of UCART123v1.2
AMELI-01:Preliminary Results from A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia David A. Sallman1, Daniel J. DeAngelo2, Naveen Pemmaraju3, Shira Dinner4, Saar Gill5, Rebecca Olin6, Eunic
Slide 9: Background and Introduction
Background and Introduction § It is estimated that 20,050 new cases and 11,540 deaths related to AML will occur in the US in 20221 § Outcomes for patients with R/R AML remain poor, with response rates <30% and an expected 5-year overall survival of <15%2,3 § AMELI-01 (NCT03190278) is a phase I, open
Slide 10: UCART123v1.2: Allogeneic Off-the-Shelf T-cell Product
UCART123v1.2: Allogeneic “Off-the-Shelf” T-cell Product UCART123v1.2 (anD-CD123 scFv- 41BB-CD3ζ): § CD123 is a validated therapeu3c target in AML § Gene3cally modified allogeneic T- cell product manufactured from non-HLA–matched healthy donor cells § TRAC disrupted using TALEN® to eliminate TCRαβ fro
Slide 11: AMELI-01 Study Design
AMELI-01 Study Design Key inclusion criteria Dose-Escalation UCART123v1.2 § Relapsed or primary refractory AML (>5% bone mTPI design ● 2-4 pts/cohort marrow blasts) FC Arm FCA Arm § Blasts expressing CD123 § PS of ≤1 and adequate organ function UCART123v1.2 UCART123v1.2 (single dose) (single dose) P
Slide 12: Baseline Characteristics
Baseline Characteristics Characteris>c Total (N = 18*) Age, median (range), years 57 (18-64) Female, n (%) 8 (44) ECOG PS 1, n (%) 17 (94) ELN 2017 Classification, n (%) Adverse risk 14 (78) Intermediate risk 3 (17) Median baseline bone marrow blasts % (range) 37 (0-88) Number of prior treatments, m
Slide 13: UCART123v1.2 - Related TEAEs (FC + FCA)
UCART123v1.2 - Related TEAEs (FC + FCA) FC FCA FC + FCA FC Total [n=8] FCA Total [n=9] All patients DL1=2; DL2=3; DL2i=2; DL3=1 DL2=8; DL2i=1 N=17* TEAE, n Any grade Gr ≥3 Any grade Gr ≥3 Any grade Gr ≥3 CRS 8 2 9 2 17 4 HLH 1 1 1 0 2 1 ICANS 1 1 1 0 2 1 ALT increased 4 1 1 1 5 2 AST increased 4 1 1
Slide 14: UCART123v1.2 - Serious TEAEs (All Cause)
UCART123v1.2 - Serious TEAEs (All Cause – FC + FCA) FC FCA FC + FCA FC Total [n=8] FCA Total [n=9] Total patients DL1=2; DL2=3; DL2i=2; DL3=1 DL2=8; DL2i=1 N=17* Serious TEAE, n (%) Any grade Gr ≥3 Any grade Gr ≥3 Any grade Gr ≥3 CRS 3 2 2 2 5 4 ICANS 1 1 0 0 1 1 Pneumonia 1 1 1 1 2 2 Pneumonia fung
Slide 15: Anti-Leukemic Activity Observed in 4/17 Patients
Anti-Leukemic Activity Observed in 4/17 Patients 100 FC Arm § FC arm 90 102-201 80 104-204 DL1 • Patient 101-219 (DL2i): SD % of Blasts in BM 70 60 101-209 • Patient 103-223 (DL2i): MLFS 50 102-208 DL2 40 30 103-207 20 101-219 10 0 103-223 DL2i -10 103-211 DL3 Screening D14 D28 FCA Arm 100 90 102-22
Slide 16: Addition of Alemtuzumab Results in Prolonged Lymphodepletion
Addition of Alemtuzumab Results in Prolonged Lymphodepletion Absolute Lymphocyte Counts FC Arm FCA Arm 10 10 102-201 102-222 5 DL1 5 104-204 103-225 2.0 2.0 101-209 103-231 ALC (K/µL) ALC (K/µL) 1.5 102-208 DL2 1.5 104-218 DL2 1.0 103-207 1.0 104-224 101-219 104-226 0.5 DL2i 0.5 103-223 114-229 0.0
Slide 17: Addition of Alemtuzumab Results in Increased UCART123v1.2 Expansion
Addition of Alemtuzumab Results in Increased UCART123v1.2 Expansion UCART123 Cell Expansion in WB by VCN VCN AUC(0-28days) 1000000 FC Arm 102-201 100000 DL1 p=0.04 100 Psi copies/µg DNA 104-204 101-209 10000 (days x copies/ug of DNA) 102-208 DL2 1000 103-207 80 100 101-219 DL2i VCN - AUC LLOQ 10 103
Slide 18: Cytokine Secretion and Ferritin Levels Correlated with Cell Expansion
Cytokine Secretion and Ferritin Levels Correlated with UCART123v1.2 Cell Expansion Cytokine Profile of All Patients from FCA Arm IL-2 IL-6 IFN-g TNF-a 10 10000 1000 10 102-222 102-222 102-222 102-222 1000 103-225 103-225 103-225 103-225 Fold change (log) Fold change (log) 100 Fold change (log) 103-2
Slide 19: Patient 104-226 Achieved a Durable MRD Negative CR
Patient 104-226 Achieved a Durable MRD Negative CR Clinical Characteristics Age, Race, Sex 64 year old white female ECOG PS 1 ELN 2017 Classification; WHO Classification Adverse risk; AML with myelodysplasia-related changes Cytogenetic and Molecular Abnormalities 45,XX,-7,t(10;12)(q24;p13)[5]; IDH1,
Slide 20: Translational Data Supports Use of a Two-Dose Regimen
Translational Data From Patient 104-226 and Others Supports Use of a Two-Dose Regimen of UCART123v1.2 § UCART123v1.2 expansion correlates with reduction in tumor burden at DL2 (6.25 x 105 cells/kg) but at this dose, UCART123v1.2 cell function is not sufficient for sustained anti- leukemic activity i
Slide 21: AMELI-01 Amended Protocol with Two-Dose Regimen Design
AMELI-01 Amended Protocol with Two-Dose Regimen Design Dose-Escalation UCART123.1.2 mTPI design; 2-4 pts/cohort FC Arm FCA Arm UCART123v1.2 UCART123v1.2 UCART123v1.2 (single dose) (single dose) (2-dose regimen) DL 3 DL 3 DL 3 x 2 SED DL 2i DL 2i DL 2i x 2 CLO DL 2 DL 2 DL 2 x 2 UCART123.v1.2 DL-1 1.
Slide 22: Conclusions
Conclusions § Adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123v1.2 cell expansion, which correlated with improved activity and cytokine profiles Ø One patient in the DL2 FCA arm achieved >90% blast reduction at Day 28 Ø One patient in the DL2 FCA
Slide 23: BALLI-01: UCART22
BALLI-01: UCART22 23
Slide 24: UCART22 – BALLI-01 Trial Design
UCART22 – BALLI-01 Trial Design Phase I/IIa, Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 in Patients with Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Determine MTD Dose Expansion Dose Escala=
Slide 25: UCART22 Administration Shows Promising Safety Profile
UCART22 Administration Shows Promising Safety Profile Patient Characteristics (N=12) Safety: FCA Cohorts (N=6) Median age: 30 (20-61) 0 dose limi=ng toxicity WHO classification: 0 ICANS (immune effector cell associated • B-ALL with recurrent genetic abnormalities: 7 neurotoxicity) (58%); 0 severe UCA
Slide 26: Patient 1
Patient 1 Age 34 Sex Male Prior Therapies 1: Induction: GRALL 2014 (Intensive chemotherapy) – Daunorubicin; vincristine; cyclophosphamide; L-asparaginase; mercaptopurine; methotrexate; etoposide; cytarabine; prednisone/dexamethasone 2: Salvage: Vincristine; HiDAC; vindesine; ifofsamide; thioguanine;
Slide 27: Patient 2
Pa-ent 2 Age 24 Sex Female Prior Therapies 1: AALL1131 high-risk arm (Intensive chemotherapy) – Vincristine; daunorubicin; prednisone/dexamethasone; cyclophosphamide; cytarabine; mercaptopurine; PEG- asparginase; methotrexate 2: Salvage: Vincristine; daunorubicin followed by autologous CD19 CART 3:
Slide 28: Patient 3
Patient 3 Age 57 Sex Male Prior Therapies 1: Induction: Vincristine; daunorubicin; cyclophosphamide; PEG-asparaginase; prednisone + consolidation: blinatumomab; cytarabine; methotrexate; vincristine; mercaptopurine; dexamethasone; followed by allogeneic HSCT (haploidentical donor) 2: Salvage: Vincri
Slide 29: Summary of UCART22 DL3 data
Summary of UCART22 DL3 data • Five subjects were dosed at DL3 (5 x 106 cells/kg) with UCART22 Process 1 (P1) using FCA LD: ‒ No safety issues, no Grade 2 or higher CRS ‒ 3 out of 5 clinical responses (60% ORR): 1 MRD neg. CR, 1 MRD neg. CRi, 1 MLFS ‒ All 3 of the responders failed multiple lines of
Slide 30: Next steps for BALLI-01
Next steps for BALLI-01 • Dosing started with UCART22 Process 2 (P2) made by Cellectis • UCART22 P2 product candidate has shown a significantly higher potency in vitro than P1 • 1st subject dosing at DL2 (1 x 106 cells/kg) • Next data set with P2 expected in 2023 30
Slide 31: Summary
SUMMARY § AMELI-01 (UCART123) § Adding alemtuzumab to the FC lymphodepletion regimen was associated with improved LD and significantly higher UCART123v1.2 cell expansion, which correlated with improved activity § One patient in the DL2 FCA arm achieved >90% blast reduction at Day 28 § One patient in
Slide 32: Discover, Create, Develop, Produce and Test
Discover, Create, Develop, Produce and Test ALPHA Study Paris New York, New York Paris, France Raleigh, North Carolina Innovation, Clinical Development HQ, PD/AD, Starting Materials UCART – Clinical & poten@al for Commercial ̴25,000 sq ^. facility 5 ̴ 5,000 sq ^. facility ̴82,000 sq ^. facility ü Ge
Slide 33: Expected 2023 Milestones
Expected 2023 Milestones UCART22 UCART123 UCARTCS1 UCART20x22 r/r B-ALL r/r AML r/r MM r/r NHL Data update with Data update with Enroll DL1 with FC 1st in human data in-house 2-dose regimen lymphodeple3on update manufactured product ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DL,
Slide 34: Thank You
Thank You Reach us at: investors@cellectis.com Cellec^s Paris Cellec^s New York Cellec^s Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA 34